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Group Investigators
Varese, Pavia, Tradate, Castellanza, Milano, Torino, Casarano, Negrar, Brescia, and Novara, Italy
Objectives The aim of this study was to assess the prognostic value of T-wave alternans (TWA) in New York Heart Associa-
tion (NYHA) functional class II/III patients with nonischemic cardiomyopathy and left ventricular ejection fraction
(LVEF) 40%.
Background There is a strong need to identify reliable risk stratifiers among heart failure candidates for implantable
cardioverter-defibrillator (ICD) prophylaxis. T-wave alternans may identify low-risk subjects among post-myocardial
infarction patients with depressed LVEF, but its predictive role in nonischemic cardiomyopathy is unclear.
Methods Four hundred forty-six patients were enrolled and followed up for 18 to 24 months. The primary end point was
the combination of cardiac death  life-threatening arrhythmias; secondary end points were total mortality and
the combination of arrhythmic death  life-threatening arrhythmias.
Results Patients with abnormal TWA (65%) compared with normal TWA (35%) tests were older (60  13 years vs. 57 
12 years), were more frequently in NYHA functional class III (22% vs. 19%), and had a modestly lower LVEF (29
 7% vs. 31  7%). Primary end point rates in patients with abnormal and normal TWA tests were 6.5% (95%
confidence interval [CI] 4.5% to 9.4%) and 1.6% (95% CI 0.6% to 4.4%), respectively. Unadjusted and adjusted
hazard ratios were 4.0 (95% CI 1.4% to 11.4%; p  0.002) and 3.2 (95% CI 1.1% to 9.2%; p  0.013), respec-
tively. Hazard ratios for total mortality and for arrhythmic death  life-threatening arrhythmias were 4.6 (p 
0.002) and 5.5 (p  0.004), respectively; 18-month negative predictive values for the 3 end points ranged be-
tween 97.3% and 98.6%.
Conclusions Among NYHA functional class II/III nonischemic cardiomyopathy patients, an abnormal TWA test is associated
with a 4-fold higher risk of cardiac death and life-threatening arrhythmias. Patients with normal TWA tests have
a very good prognosis and are likely to benefit little from ICD therapy. (J Am Coll Cardiol 2007;50:1896–904)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.004‡
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November 6, 2007:1896–904 T-Wave Alternans in Heart Failureardioverter-defibrillators (ICDs) in patients with heart failure
nd left ventricular ejection fraction (LVEF) 35% has
ignificantly improved survival (2). However, the absolute
enefit is relatively small (7.2% over 5 years). Because of the
sychologic and economic burden as well as the potential
or side effects, controversies exist concerning an ap-
roach of widespread primary prophylaxis with ICDs (3).
herefore, there is a need for better risk stratifiers (4), as
lso recognized by the Centers for Medicare and Med-
caid Services (CMS) (5). A marker with a high negative
redictive value (NPV) would be particularly useful to
dentify patients who are unlikely to benefit from ICD
rophylaxis despite the presence of heart failure and left
entricular dysfunction.
Among patients with prior myocardial infarction and
VEF 30%, T-wave alternans (TWA) may identify
atients who are likely and not likely to benefit from ICD
herapy (6). There are limited and conflicting data regarding
he prognostic value of TWA in patients with heart failure
ue to nonischemic cardiomyopathy (7–13), a setting in
hich the search for reliable risk stratifiers has been partic-
larly frustrating (14,15).
Accordingly, we designed and conducted a multicenter,
rospective, longitudinal, observational study to assess the
apability of TWA to predict cardiac death and life-
hreatening arrhythmias among consecutive patients with
ew York Heart Association (NYHA) functional class II
nd III heart failure due to nonischemic cardiomyopathy
nd LVEF 40%.
ethods
atient selection. Every patient seen at the heart failure
linics of the 9 participating Italian hospitals during the
eriod of enrollment was screened for eligibility for the
tudy. The design of the study has been previously published
16). The study was approved by the ethical committees of
ach participating center. Overall, 3,513 patients were
creened and constitute the ALPHA (T-Wave Alternans in
atients With Heart Failure) registry, a source of potentially
seful epidemiologic data (17). Among these patients, main
oneligibility criteria (more than 1 could be present) were:
ther etiology, mainly ischemic, of the cardiomyopathy (n
1,608); presence of atrial fibrillation or flutter at the time
f screening (n  778); LVEF 40% (n  719); NYHA
unctional class I or IV (n  545); age 18 or 80 years (n
134); the presence of an implanted pacemaker or ICD (n
373); and a history of cardiac arrest, sustained ventricular
achycardia, or syncope, or a clear-cut indication for ICD
mplantation (mostly class I indications following the guide-
ines active at the time of patient enrollment, such as
econdary prevention) (n  65). Logistical reasons pre-
ented enrollment 42 patients, and 46 refused written
nformed consent to the study. Compared with enrolled
atients, eligible but not enrolled patients (n  88) had the
ame age (59.2  12.7 years), LVEF (29.3  6.3%), crevalence of NYHA functional
lass III (20%), and QRS interval
uration (123.7  30.5 ms).
Overall, 446 patients (349
ale, 97 female) entered the
tudy. Three hundred twenty-six
atients had idiopathic dilated
ardiomyopathy, 72 had a hyper-
ensive etiology, 9 had a valvular
tiology, and 39 had other etiol-
gies. Coronary angiography was
ighly recommended to establish
he diagnosis of nonischemic
ardiomyopathy, with the excep-
ion of young patients with fa-
iliar/genetic cardiomyopathy,
nd was available for almost ev-
ry patient. The first patient was
nrolled in June 2001, the last in
uly 2004. Each patient’s medical
istory was recorded on enroll-
ent; physical examination,
chocardiographic evaluation,
4-h Holter monitoring, assess-
ent of quality of life by means of the Minnesota Living
ith Heart Failure questionnaire, and cardiopulmonary
xercise test with measurement of peak O2 uptake were
arried out in addition to TWA testing.
WA testing. Patients performed the TWA exercise test
hile taking their regular medications, including beta-
lockers. The exercise was performed on a bicycle in 83% of
ases and on a treadmill in 17% of cases.
Careful skin preparation and high-resolution electrodes
ere used to minimize noise. Electrocardiographic leads
ere placed at the standard 12-lead positions and in an
rthogonal X, Y, and Z configuration. Measurements were
ade with a CH2000 or Heartwave system (Cambridge
eart, Bedford, Massachusetts) and used a spectral method
f analysis designed to allow detection of alternans in the
icrovolt range of amplitude (18). The TWA test was
utomatically interpreted within the CH2000 or Heartwave
ystem by the Alternans Report Classifier (version D10 used
n all centers; Cambridge Heart) and classified according to
reviously described criteria (19). This classification was
one locally in each center. An expert in TWA classification
as present during the first 5 tests in each center and was
vailable thereafter as external support to facilitate the
earning curve and to ensure uniformity throughout the
ifferent centers. The expert was always blinded to patient
haracteristics. The original protocol designed in the year
000 planned to compare positive and negative TWA tests.
owever, studies published during the enrollment phase of
he present trial revealed that positive and indeterminate
WA tests have similar event rates, suggesting that they
hould be grouped together as abnormal tests and be
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CI  confidence interval
CRT  cardiac
resynchronization therapy
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
NPV  negative predictive
value
NYHA  New York Heart
Association
PPV  positive predictive
value
TWA  T-wave alternans
VF  ventricular fibrillation
VT  ventricular
tachycardiaompared with normal (negative) TWA tests (19–21).
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T-Wave Alternans in Heart Failure November 6, 2007:1896–904herefore, before the study was closed, the steering com-
ittee decided to make all comparisons between patients
ith abnormal and patients with normal TWA tests, an
pproach that has been adopted in all recent studies (22,23).
ollow-up. Patients were evaluated every 6 months up to
8 months, as planned in the protocol of the study.
ollow-up could be extended to 24 months according to
nvestigator willingness and was censored at the first event
ecorded.
nd points. All end points were adjudicated by an events
ommittee that was unaware of the TWA test results.
eaths were classified according to the Hinkle-Thaler (24)
ystem, as modified in the MUSTT (Multicenter Unsus-
ained Tachycardia Trial) study (25).
The prognostic role of TWA was assessed for the
ombined primary end point of cardiac death and life-
hreatening ventricular arrhythmias (ventricular fibrillation,
esuscitated cardiac arrest, and sustained ventricular tachy-
ardia either symptomatic or revealed by a subsequently
mplanted device).
The prognostic role of TWA was also assessed for the
ollowing secondary end points: 1) total mortality; 2) a com-
ined end point of arrhythmic death and life-threatening
rrhythmias; and 3) hospitalization rate.
tatistical analysis. Data were described as mean and
tandard deviation for continuous variables and as count and
ercentage for categoric variables. Median follow-up and its
5th to 75th percentile (interquartile) range was calculated
ith the inverse Kaplan-Meier method (26). Baseline char-
cteristics (Table 1) were compared between TWA groups
y means of general linear models.
For each TWA group, we computed the rates of events
er 100 person-years, together with their 95% confidence
ntervals (CIs) and the Kaplan-Meier cumulative event-free
urvival. We used the log-rank test to compare groups and
tted a Cox model to estimate hazard ratios (HRs) and 95%
Is for the prognostic role of TWA. We computed the
nadjusted HR and the HR adjusted for age, gender,
YHA functional class, and LVEF in a multivariable
nalysis. The proportional hazards assumption was tested by
eans of Schoenfeld residuals (27). The assumption was
atisfied in all cases (p  0.05). To account for all of the
aseline characteristics differing between TWA groups with
p value of 0.10 or less (age; gender; NYHA functional
lass; LVEF; left ventricular end-systolic volume; use of
eta-blockers, angiotensin-converting enzyme [ACE] in-
ibitors aldosterone antagonists, or digoxin; QRS duration
120 ms; presence of left bundle branch block; and quality
f life), data reduction was performed by means of factor
nalysis (using the principal components method), and the
rst 3 factors were included in the model together with
WA. We calculated the NPV and positive predictive value
PPV) of the TWA test for the prediction of events at 12
nd 18 months. We compared rates of hospitalization by
eans of a Poisson model for counts and computed thencidence rate ratios and 95% CI to quantify the association. (ll tests were 2 sided. A p value of 0.05 was used for
tatistical significance. Stata 9 (StataCorp, College Station,
exas) was used for computation.
esults
aseline characteristics. Among the 446 patients enrolled,
54 (34.6%) had negative, 200 (44.8%) positive, and 92
20.6%) indeterminate TWA tests. Causes of indeterminate
ests included frequent ventricular arrhythmia (13%), noise
5%), and inadequate heart rate levels (5%). In case of a
eart rate level lower than needed in the first test, the
uggestion was made to perform a second TWA test to
educe the number of indeterminate tests. Baseline charac-
eristics of the overall population and of the 154 normal and
92 abnormal (positive indeterminate) TWA patients are
ummarized in Table 1. Patients with abnormal TWA tests
ere 2.5 years older, had a worse quality of life, and were
ore frequently in NYHA functional class III. They also
howed larger left chamber sizes and lower LVEF. How-
ver, the cardiopulmonary test, available in 70% of the
ohort, yielded comparable results in the 2 groups for both
aximal exercise O2 consumption and Weber classification.
oncerning pharmacologic therapy, digitalis and ACE
nhibitors were administered more frequently in the abnor-
al TWA test group.
vents during follow-up. Follow-up was completed in
00% of the patients. The main events occurring during the
edian follow-up of 19 months (interquartile range 18 to
0 months) are listed in Table 2.
Table 3 shows the rates of the end points occurring in the
verall population and the HRs associated with an abnormal
WA test, as well as the NPV and PPV of the test. The
rimary end point (cardiac death  life-threatening ar-
hythmia) was reached in 29 of 292 patients (9.9%) from the
bnormal and 4 of 154 patients (2.6%) from the normal
WA test group (Fig. 1). In the Cox model, the unadjusted
R for the primary end point was 4.01 (95% CI 1.41 to
1.41; p  0.002). In a multivariable analysis, the HR
djusted for age, gender, NYHA functional class, and
VEF was 3.21 (95% CI 1.12 to 9.22; p  0.013) and the
R adjusted for digoxin, ACE inhibitor, aldosterone an-
agonist, and beta-blocker treatment was 4.23 (95% CI 1.46
o 12.21; p  0.0018). In the data reduction model that
ccounted for: age; gender; NYHA functional class; LVEF;
eft ventricular end-systolic volume; use of beta-blockers,
CE inhibitors, aldosterone antagonists, or digoxin; QRS
uration 120 ms; presence of left bundle branch block;
nd quality of life, the HR for TWA was 3.98 (95% CI 1.20
o 13.27; p  0.008).
The NPV of a normal TWA test at 12 and 18 months
xceeded 97% (Table 3). A significantly increased risk was
lso found when comparing patients with a positive versus
atients with a negative TWA test, with an HR of 3.16
95% CI 1.06 to 9.45; p  0.023).
e
b
b
a
ts; QOL
lternan
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November 6, 2007:1896–904 T-Wave Alternans in Heart FailureAt the time of screening, patients were evaluated for
ligibility for a biventricular device. The indication for a
Baseline Characteristics According to TWA Tes
Table 1 Baseline Characteristics According
Characteristic
Overall Population
(n  446)
General
Age (yrs) 59.0 (12.5)
Gender (male) 349 (78.2%)
HF duration (yrs) 4.0 (4.3)
NYHA functional class III 75 (16.2%)
Hb (g/dl) 14.0 (1.5)
Plt (103/l) 216.1 (55.8)
Na (mEq/l) 139.9 (3.4)
K (mEq/l) 4.2 (0.4)
Creatinine (mg/dl) 1.03 (0.33)
BMI (kg/m2) 26.7 (4.5)
SBP (mm Hg) 124.5 (16.8)
DBP (mm Hg) 76.0 (12.8)
Minnesota QOL score 20.9 (16.1)
History of
Stroke 10 (2.3%)
Peripheral artery disease 11 (2.6%)
Hypertension 168 (38.4%)
Diabetes 57 (13.0%)
Electrocardiogram
Heart rate (beats/min) 74.1 (13.9)
IVCD
No 248 (55.6%)
LBBB 190 (42.6%)
RBBB 8 (1.8%)
QRS (ms) 124.9 (33.4)
Echocardiographic findings
LVEDD (mm) 66.7 (8.1)
LVESD (mm) 55.1 (9.6)
LA (mm) 44.4 (7.1)
LVEDV (ml) 208.7 (79.0)
LVESV (ml) 149.2 (66.9)
LVEF (%) 29.5 (7.1)
Cardiopulmonary test (n  311)
Peak VO2 (ml/kg/min) 16.8 (5.8)
Weber
1 87 (27.9%)
2 96 (30.9%)
3 101 (32.5%)
4 27 (8.7%)
Treatment
ACE inhibitors 381 (85.4%)
Beta-blockers 357 (80.0%)
Digitalis 168 (37.7%)
Diuretics 394 (88.3%)
Aldosterone antagonists 159 (36.7%)
Antiarrhythmics 88 (19.7%)
Values in parentheses are standard deviations for continuous variable
ACE  angiotensin-converting enzyme; BMI  body mass index; DB
intraventricular conduction delay; LA left atrium; LBBB left bundle
ventricular end-diastolic volume; LVEF  left ventricular ejection fract
end-systolic volume; NYHA New York Heart Association; Plt platele
bundle branch block; SBP  systolic blood pressure; TWA  T-wave aiventricular device was given independently, in most cases 3efore the TWA test, and was based on the presence of
dvanced NYHA functional class and wide QRS. Overall,
A Testing
bnormal TWA Test
(n  292)
Normal TWA Test
(n  154) p Value
59.9 (12.7) 57.4 (12.1) 0.042
229 (78.4%) 120 (77.9%) 0.904
4.2 (4.5) 3.5 (3.8) 0.375
57 (19.2%) 18 (11.7%) 0.045
14.0 (1.5) 14.0 (1.6) 0.871
216.6 (56.3) 215.2 (55.0) 0.805
139.8 (3.75) 140.0 (2.7) 0.453
4.24 (0.46) 4.25 (0.44) 0.779
1.02 (0.34) 1.04 (0.30) 0.581
26.6 (4.6) 27.0 (4.5) 0.404
124.1 (16.7) 125.2 (16.9) 0.503
77.4 (8.7) 78.4 (9.1) 0.299
22.9 (17.1) 17.0 (13.1) 0.001
9 (3.1%) 1 (0.6%) 0.176
5 (1.9%) 6 (4.0%) 0.210
102 (35.8%) 66 (43.1%) 0.149
39 (13.6%) 18 (11.8%) 0.657
74.4 (14.6) 73.7 (12.5) 0.576
0.036
154 (52.7%) 94 (61.0%)
130 (44.5%) 60 (39.0%)
8 (2.7%) 0 (0%)
126.8 (33.3) 121.2 (33.6) 0.090
67.9 (8.0) 64.6 (7.9) 0.001
56.8 (9.2) 51.9 (9.6) 0.001
45.5 (7.1) 42.4 (6.9) 0.001
217.7 (79.3) 193.1 (76.2) 0.004
157.6 (66.4) 134.3 (65.5) 0.001
28.6 (6.9) 31.3 (7.29) 0.001
16.7 (5.7) 17.1 (5.9) 0.519
0.253
60 (29.0) 27 (26.0%)
57 (27.5%) 39 (37.5%)
73 (35.3%) 28 (26.9%)
17 (8.2%) 10 (9.6%)
258 (88.4%) 123 (79.9%) 0.023
232 (79.4%) 125 (81.2%) 0.710
123 (42.1%) 45 (29.2%) 0.008
263 (90.1) 131 (85.1%) 0.123
103 (35.3%) 56 (36.4%) 0.836
56 (19.2%) 32 (20.8%) 0.708
rcentages for discrete variables.
stolic blood pressure; Hb  hemoglobin; HF  heart failure; IVCD 
block; LVEDD left ventricular end-diastolic diameter; LVEDV left
SD  left ventricular end-systolic diameter; LVESV  left ventricular
 Living With Heart Failure quality of life questionnaire; RBBB right
s; VO2  oxygen uptake.ting
to TW
A
s or pe
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T-Wave Alternans in Heart Failure November 6, 2007:1896–904esynchronization therapy (CRT): 17 were implanted
ith a CRT-pacing device (15 of 17 in NYHA functional
lass III, average QRS duration 182  24 ms, 16 with
bnormal and 1 with a normal TWA test) and 14 were
mplanted with a CRT-defibrillator device (11 of 14 in
YHA functional class III, average QRS duration 166 
9 ms, 12 with abnormal and 2 with normal TWA tests).
n the late part of the study, following the most recent
vidence of ICD benefit among NYHA functional class II
nd III patients (28), 21 additional patients were implanted
ith an ICD (16 with abnormal and 5 with normal TWA
ests).
The imbalance in the proportion of patients with an
mplanted device in the abnormal TWA test group may
ave led to a slight overestimation of the rate of events in
his group. Accordingly, we performed a sensitivity analysis
f the primary end point by dropping the 4 events identified
hrough the device (all in the abnormal TWA test group).
he event rate in this group decreased from 6.5 to 5.7 (95%
I 3.8 to 8.4), and the corresponding HR with respect to
atients with normal TWA tests decreased from 4.00 to
.44 (95% CI 1.20 to 9.90; p  0.008), still denoting a
ignificant excess risk in the abnormal TWA test group. An
nalysis was also performed dropping all patients with an
Events During Follow-Up
Table 2 Events During Follow-Up
Event
Overall Populat
(n  446)
Total mortality 28 (6.3%)
Cardiac death 18 (4.0%)
Sudden death 7 (1.6%)
Symptomatic sustained VT or VF 11 (2.5%)
Documented VF 4 (0.9%)
Sustained VT revealed by device 4 (0.9%)
Hospitalization 85 (19.1%)
TWA  T-wave alternans; VF  ventricular fibrillation; VT  ventricula
ole of TWA Tests (Abnormal vs. Normal) on the End Points
Table 3 Role of TWA Tests (Abnormal vs. Normal) on the End P
End Point
No. of Events Rate* (95% CI)
Abnormal
TWA Test
Normal
TWA Test
Abnormal
TWA Test
Normal
TWA Test
Primary end point
Cardiac death 
life-threatening
arrhythmia
29 4 6.5
(4.5–9.4)
1.6
(0.6–4.4)
Secondary end
points
Total mortality 25 3 5.7
(3.8–8.4)
1.2
(0.4–3.8)
Arrhythmic death 
life-threatening
arrhythmia
20 2 4.5
(2.9–7.0)
0.8
(0.2–3.3)
Hospitalization 61 24 13.8
(10.6–17.8)
9.9
(6.3–14.7)
Rate is expressed as events per 100 person-years (number of events/sum of follow-up times in
rediction of events at 12 and 18 months. ‡Positive predictive value of an abnormal TWA test (and 95%
CI  confidence interval; HR  hazard ratio; NPV  negative predictive value; PPV  positive predictivmplanted biventricular device; the HR associated with an
bnormal TWA test was found to be 3.43 (95% CI 1.19 to
.92; p  0.009). Finally, an analysis was performed
xcluding the 5 cases of indeterminate TWA tests because
f noise; the HR associated with an abnormal TWA test
as found to be 3.93 (95% CI 1.38 to 11.21; p  0.010).
Results of the secondary end points are consistent with
hose of the primary end point and show a significant
ncrease in risk in the abnormal TWA test group for both
vent-free survival curves (Fig. 2). Negative predictive
alues between 99.3% and 98% were found at 12 and 18
onths, for both total mortality and arrhythmic death 
ife-threatening arrhythmias. On the other hand, the rate of
ospitalization tended to be higher in the abnormal TWA
est group, but the difference did not reach statistical
ignificance.
Positive predictive values were relatively low (6.5% and
.0% for the primary end point at 12 and 18 months) (Table
), slightly increasing to 7.9 and 10.9 at 12 and 18 months,
espectively, among patients with LVEF 35%.
No significant interaction was found between TWA
rediction and either QRS duration or LVEF. Specifically,
he predictive role of the TWA test was only marginally
nfluenced by the presence of QRS enlargement. The NPV
Normal TWA Test
(n  154)
Abnormal TWA Test
(n  292)
3 (1.9%) 25 (8.6%)
2 (1.3%) 16 (5.5%)
0 7 (2.4%)
2 (1.3%) 9 (3.1%)
0 4 (1.4%)
0 4 (1.4%)
24 (15.6%) 61 (20.9%)
ardia.
HR
5% CI)
p
Value
NPV† (95% CI) PPV‡ (95% CI)
12 months 18 months 12 months 18 months
–11.41)
0.002 98.7%
(95.4–99.8)
97.3%
(93.3–99.3)
6.5
(4.0–10.0)
9.0
(5.9–13.0)
–15.25)
0.002 99.3%
(96.4–100)
98.0%
(94.2–99.6)
4.2
(2.2–7.3)
7.7
(4.1–11.5)
–23.65)
0.004 99.3%
(96.4–100)
98.6%
(95.2–99.8)
4.9
(2.7–8.1)
7.0
(4.3–10.7)
1.39
–2.32)
0.165
100 persons). †Negative predictive value of a normal TWA test (and 95% CI) with respect to theionoints
(9
4.01
(1.41
4.60
(1.39
5.53
(1.29
IRR
(0.86
years/
CI) with respect to the prediction of events at 12 and 18 months.
e value; TWA  T-wave alternans.
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November 6, 2007:1896–904 T-Wave Alternans in Heart Failureor a normal TWA test relative to the primary end point of
he study at 12 months was 99% among patients with a
RS duration 120 ms and 98.3% among patients with a
RS duration 120 ms. Conversely, the PPV for the same
nd point was 5.6 and 7.7 among patients with QRS
urations 120 and 120 ms, respectively.
Because recent guidelines advocate ICD implantation for
eart failure patients with LVEF 35%, we assessed the
redictive role of TWA in this subgroup of patients (n 
39). Within this group of patients, the event rates of the
rimary end point were 8.1 (95% CI 5.6 to 11.6) per 100
erson-years among patients with abnormal TWA tests and
.9 (95% CI 0.6 to 5.9) per 100 person-years among
atients with normal TWA tests. The unadjusted and
djusted HRs associated with an abnormal TWA test were,
espectively, 4.28 (95% CI 1.30 to 14.05; p  0.004) and
.91 (95% CI 1.18 to 12.90, p  0.025), and the NPVs at
2 montsh and 18 months were, respectively, 99.0% (95%
I 94.4 to 100) and 96.8% (95% CI 91.0 to 99.3).
iscussion
he present study aimed to assess the capability of TWA to
redict cardiac death and life-threatening arrhythmias
mong patients with NYHA functional class II and III heart
ailure due to nonischemic cardiomyopathy and LVEF
40%. The presence of an abnormal TWA test was
ssociated with an increased risk of death and arrhythmic
vents, and the test allowed identification of a large group of
atients who have an excellent prognosis and are unlikely to
enefit from ICD prophylaxis despite the presence of heart
ailure and left ventricular dysfunction.
There is a great need to stratify patients at risk for sudden
Figure 1 Freedom From Cardiac Death 
Life-Threatening Arrhythmias
Primary end point: Kaplan-Meier cumulative event-free survival according to
T-wave alternans (TWA) test. Patients at risk at selected time points are
reported.ardiac death, especially among patients with nonischemicardiomyopathy (3–5). The American College of Cardiol-
gy/American Heart Association/European Society of Car-
iology 2006 guideline for management of patients with
entricular arrhythmias and prevention of sudden cardiac
eath (4) suggests for the first time that the use of TWA is
easonable for risk stratification of patients who are at risk
or developing life-threatening ventricular arrhythmias. The
ecommendation is classified as class IIa, indicating the
resence of not completely conclusive data and some con-
icting evidence.
The favorable evidence derives mostly from patients with
schemic cardiomyopathy (6,23,29). However, the mecha-
isms of arrhythmias in patients with nonischemic heart
ailure (30,31) are quite different from those present in
atients with a previous myocardial infarction. Evaluation of
he arrhythmogenic substrate, by means of electrophysi-
logic testing and signal-averaged electrocardiogram, ap-
A
B
Figure 2 Freedom From Total Mortality and Arrhythmic
Death  Life-Threatening Arrhythmias
Secondary end points: (A) Kaplan-Meier cumulative survival (total mortality)
and (B) Kaplan-Meier event-free survival (arrhythmic death  life-threatening
arrhythmias) according to T-wave alternans (TWA) test.
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T-Wave Alternans in Heart Failure November 6, 2007:1896–904ears to provide prognostic information in patients with a
revious myocardial infarction (25,28–34) but not in pa-
ients with nonischemic cardiomyopathy (5,35).
Data on a predictive role of TWA in patients with
onischemic cardiomyopathy are relatively limited and
resent conflicting evidence. Klingenheben et al. (7) studied
07 patients with heart failure (40 nonischemic) and LVEF
45%. Arrhythmic end points occurred in 11 of 52 patients
ith positive, 2 of 22 patients with indeterminate, and 0 of
3 patients with negative TWA tests (p 0.005). Kitamura
t al. (9) studied 104 patients and Hohnloser et al. (10) 137
atients with nonischemic cardiomyopathy. In both reports,
ata showed a significant predictive power of TWA for
rrhythmic events. Nevertheless, some limitations were
resent in both reports; in the first study, no LVEF cutoff
as selected and patients were not treated at baseline with
eta-blockers or ACE inhibitors, and in the second, 37 of
37 patients (27%) were already implanted with an ICD,
ostly because of previous cardiac arrest or documented
entricular tachycardia.
Grimm et al. (11) studied 263 patients with nonischemic
ardiomyopathy, a mean age of 48 years, and LVEF of 30%,
nd mostly in NYHA functional classes II and III. Fifty
ercent of the patients were on beta-blockers at the time of
ntry, but the drug was withheld before the TWA test in
lmost all of the patients. During the 52-month follow-up,
rrhythmic events occurred in 18 of 137 patients (13%) with
ositive, 13 of 54 patients (24%) with indeterminate, and 7
f 72 patients (10%) with negative TWA tests. On multi-
ariate analysis, only LVEF was a predictor of arrhythmic
vents and TWA was not. Potential limitations of the study
re the beta-blocker withdrawal before the test, their non-
niform use during the follow-up period, and the loss of a
onsiderable number of patients to cardiac transplantation.
lso, positive and indeterminate TWA tests were analyzed
eparately, rather than together as suggested by the most
ecent studies (19–23).
Finally, the recent study by Bloomfield et al. (22) in-
luded 282 nonischemic patients. The patients had an
VEF 40%, and almost two-thirds were in NYHA
unctional classes II and III. Over a 16-month follow-up,
.6% of the patients with abnormal TWA tests died
ompared with 0% of patients with normal TWA tests.
We believe the present data contribute significantly to
his area of study. First, the study represents the largest
opulation studied so far. Second, unlike all previous stud-
es, only patients in NYHA functional classes II and III
ere enrolled, mirroring class I candidates for ICD implan-
ation proposed by the recent guideline (4). Finally, consec-
tive patients were prospectively enrolled, thus minimizing
he risk of selection bias present in previous studies.
We found that patients with abnormal TWA tests had a
- to 6-fold higher likelihood of all-cause mortality and
rrhythmic end points. This also occurred after adjusting for
aseline confounding variables as well as omitting from the onalysis the arrhythmic end points revealed by the im-
lanted device to control for this potential bias.
More importantly, patients with normal TWA tests had
n extremely good outcome, with a 1.2 annual mortality rate
nd a 0.8 annual rate of arrhythmic death life-threatening
rrhythmia. After 18 months’ follow-up, the rate of cardiac
eath  life-threatening arrhythmias, total mortality, or
rrhythmic death  life-threatening arrhythmias ranged
rom 2.7% to 1.4%. Accordingly, the NPVs ranged from
7.3% to 98.6%.
Given the potential complications and adverse effects
elated to ICDs (36–39), as well as the costs of ICD
herapy, the present data suggest that a normal TWA test is
seful in identifying individuals who are unlikely to benefit
rom ICD implantation.
The PPV of the test was relatively low, as expected (9%
or the primary end point over 18 months); it increased
odestly when combined with other variables (10.3%
mong patients with QRS 120 ms and 10.9% among
atients with LVEF 35%).
tudy limitations. As in all studies evaluating TWA, we
ould not include patients with atrial fibrillation. However,
hese patients are known to be at higher risk compared with
atients in sinus rhythm (31), and the NPV of any prog-
ostic test would be weaker.
Less than one-half of the deaths observed during the
tudy were sudden arrhythmic, and the overall event rate
as relatively low. For instance, the 1-year all-cause mor-
ality rate we observed (4.2%) was lower than that (6.2%)
ound in the conventional treatment arm of the DEFINITE
Defibrillators in Nonischemic Cardiomyopathy Treatment
valuation) trial (40). Three main differences in the patient
opulation are likely to underlie this apparent discrepancy.
irst, the upper cutoff value for LVEF was 35% for the
EFINITE trial and 40% for the present trial, and the
verage LVEFs were 21.4% and 29.5%, respectively. Sec-
nd, the presence of ambient arrhythmias was required for
nrollment in the DEFINITE trial. Third, 24.5% of pa-
ients in the DEFINITE trial had atrial fibrillation, a
ondition associated with a worse prognosis, as mentioned
n the preceding text (31). Conversely, Bloomfield et al.
22), similarly to the present study, excluded patients with
trial fibrillation and patients with LVEF 40%. They
eported a 2-year combined event rate of all-cause mortality
nonfatal sustained ventricular arrhythmias in the non-
schemic population of 8.9% (compared with 10.2% in the
resent study).
Therefore, the event rate of the present study is not lower
han that reported by the most recent studies when the
ifferent patient populations are taken into account. Also,
ecause we enrolled consecutive unselected patients, at
ariance with clinical trials, we believe the conclusions
eached in the present study can be reliably transferred to
linical practice. It is important to point out that higher
vent rates would lead to lower NPVs. For instance, in case
f a 47% greater 1-year mortality, as observed in the
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November 6, 2007:1896–904 T-Wave Alternans in Heart FailureEFINITE study, the corresponding NPV would decrease
rom 99.3% to 99.0%, which is still a rather high value.
imilarly, the NPV among the subgroup of patients with
VEF 35% was also found to be high.
Finally, the predictive value was only assessed over the
8-month minimum follow-up period. Future studies will
eed to evaluate whether TWA testing should be repeated
o allow dynamic risk assessment.
onclusions
he present study assessed the prognostic capability of
WA among patients with NYHA functional class II and
II heart failure due to nonischemic cardiomyopathy and
VEF 40%. An abnormal TWA test was associated with
4-fold higher risk of cardiac death  life-threatening
entricular arrhythmias over an 18-month follow-up.
linical implications. The most important clinical impli-
ations derive from the finding that patients with a normal
WA test appear to have a very good prognosis, as shown
y the high NPV of the test. Although additional confir-
atory studies are needed before advocating a change in the
urrent treatment guidelines, the results of the present study
uggest that TWA may be effectively used to identify a
ubgroup of patients who are likely to have little benefit
rom ICD therapy despite heart failure and left ventricular
ysfunction.
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